Background We evaluated the effects of a novel platelet fibrinogen receptor antagonist, Integrelin, and a direct thrombin inhibitor, recombinant hirudin, given together with recombinant tissue plasminogen activator (rTPA) in a canine experimental model of intracoronary thrombosis. We tested the hypothesis that combination of both agents at low doses would have an additive antithrombotic effect, resulting in a significant improvement in the efficacy of rTPA.
Methods and Results Thirty-two dogs with an electrically induced coronary thrombus were treated with rTPA (1 mg/kg over 20 minutes) together with one of the following adjunctive treatments in a random fashion. Eight dogs received saline for 90 minutes; Integrelin (5 jug. kg`minm1 for 90 minutes) was given to 8 dogs; 8 dogs received recombinant hirudin (20 ,gg kg`min`for 90 minutes); and 8 dogs were treated with a low-dose combination of Integrelin (2.5 ,g kg`. min-') plus recombinant hirudin (10 ugg kg`min-1) for 90 minutes.
Integrelin or recombinant hirudin, when given as single adjunct to rTPA, enhanced the lysis of the occlusive thrombus, causing full restoration of coronary blood flow (100% of its T here is considerable evidence that contemporary methods of thrombolysis are suboptimal, due in part to the platelet-rich consistency of the arterial thrombi and to the procoagulant effects of thrombin, which is largely generated after the initial lysis of the occlusive thrombus. [1] [2] [3] [4] The current standard adjunctive treatment with thrombolysis is aspirin and heparin.5-8 However, aspirin is a relatively weak platelet inhibitor, which mainly interrupts the thromboxane pathway,9 and heparin is an indirect thrombin antagonist, which is easily inactivated by natural inhibitors and, perhaps more important, is incapable of binding clotbound thrombin.0, 11 Recently, the final common pathway of platelet aggregation, mediated throughout the activation of the lIb/llla glycoprotein receptors, has been targeted through several pharmacological preparations.12"3 Hi- rudin, a protein generated by leeches and now produced in large quantities through recombinant DNA technol-ogy, has clear advantages over heparin. Hirudin is a much smaller molecule (MW, 6964) than heparin, penetrates the thrombus, and inactivates both free and fibrin-bound thrombin. 14 With these considerations in mind, we designed the present study to assess the effects of Integrelin, a novel platelet fibrinogen receptor antagonist (a KGD inhibitor), and of recombinant hirudin, a direct antithrombin agent, on reocclusion after thrombolysis with recombinant tissue plasminogen activator (rTPA) in a canine model of acute coronary thrombosis. In addition, we tested the hypothesis that the combination of both agents at low doses would show an additive antithrombotic effect, improve the extent of reperfusion, and further reduce the reocclusion rate.
Methods

Coronary Artery Thrombosis
The methodology to induce an occlusive coronary thrombus has been described elsewhere.15-18 Briefly, 32 mongrel dogs of either sex (weight, 20±0.5 kg) were anesthetized with pentobarbital sodium (25 mg/kg), intubated, and placed on assisted ventilation with a respirator (Bear Medical Systems). A left thoracotomy was performed in the fifth intercostal space, and the heart was suspended in a pericardial cradle. The circumflex coronary artery (Cx) was isolated distal to the first diagonal branch for a length of 2 cm. An ultrasonic Doppler flow probe (Crystal Biotech) was placed on the Cx to measure was given over a 20-minute period, whereas the adjunctive treatment was infused for 90 minutes. Blood samples were collected before thrombus formation, as control, at the end of rt-PA administration, and at the end of adjunctive treatment administration.
None of the animals received aspirin or heparin. In the combination group, the doses of Integrelin and recombinant hirudin were chosen to be exactly half of those given in the monotherapy regimens.
Thrombolysis was defined as restoration of CBF to at least 30% of the baseline value, occurring at any time after the onset of rTPA infusion. Reocclusion was defined as occurrence of zero blood flow after successful initial thrombolysis.
Dogs were observed for a 2-hour period from the occurrence of thrombolysis for evidence of coronary reocclusion. As such, if reocclusion did not occur, the maximal duration of reperfusion was 120 minutes. In those dogs in which restoration of CBF was intermittent because of the cyclic flow variations, the total duration of reperfusion was calculated as the length of time during which blood flow was greater than zero during the 2-hour period after onset of reperfusion. Two hours after the onset of thrombolysis, dogs with persistent zero blood flow as well as dogs with cyclic flow variations were considered to have reocclusion of the coronary artery. Lidocaine was administered as necessary to control ventricular arrhythmias during the study.
Studies of Platelet Aggregation and Coagulation Activity Platelet Aggregation
Peripheral venous blood samples were collected in 3.8% sodium citrate (9:1 v/v), and platelet-rich plasma (PRP) was obtained by centrifuging the blood at 150g for 15 minutes at 24°C. Platelet-poor plasma (PPP) was obtained by further centrifugation at 1500g for 15 minutes. Platelet counts in PRP were adjusted to 2. Fibrinogen was determined in plasma using the von Clauss method20 using the ST4 Coagulation Timer.
TAT complexes2' are protease-antithrombin III complexes formed after thrombin generation and are markers for in vivo thrombin generation and activity. TAT complex levels were determined in plasma using a commercially available enzymelinked immunosorbent assay kit (Asserachrom ATM, American Bioproduct Co, Parsippany, NJ). Species cross-reactivity for both FPA and TAT was tested. Nonanticoagulated canine and human blood samples were allowed to clot for 15 minutes. Serum was prepared by centrifugation at 2000g for 15 minutes at 4°C. Canine samples showed 40% to 50% cross-reactivity for FPA and 80% to 100% cross-reactivity for TAT compared with human samples.
Blood samples for the above determinations were collected at the following time points: before thrombus formation (as baseline), on termination of rTPA infusion, and at the end of the adjunctive therapy administration (Fig 2) . Data were analyzed with regard to the maximal CBF, its duration, and the time from the infusion of drug to the onset of reperfusion (time to reflow) using ANOVA for repeated measures followed by t test for unpaired and paired observations where applicable. In addition, the magnitude of restored CBF, calculated over time during reperfusion, was chosen to quantify the extent of thrombolysis. Frequency of reperfusion and reocclusion were analyzed by Fisher's Exact Test. Effects of treatments on platelet aggregation and coagulation studies were analyzed by Student's t test. All data are expressed as mean±SEM. Two-sided P<.05 was considered statistically significant. Fig 3) . Although the peak CBF reached during the reperfusion was similar among the four groups of dogs (Table 1) , we observed important differences in the magnitude of restored CBF over time during the reperfusion (Fig 3) . In the rTPA-plus-saline group, CBF was restored to its baseline value for just 5±1 minutes. In the rTPA-plusIntegrelin and rTPA-plus-recombinant hirudin groups, the magnitude of CBF during reperfusion was greater than or equal to its baseline value for 29±+16 and 26±5 minutes, respectively (both P .05 versus rTPA-plus-saline group). These observations indicate that either Integrelin or recombinant hirudin, when associated with rTPA, produced greater lysis of the occlusive thrombus than the thrombolytic therapy alone. Furthermore, in dogs treated with rTPA plus Integrelin plus recombinant hirudin at low doses, CBF was restored to its baseline value for 92+19 minutes (P<.01 versus all treatments). This effect, along with the significant increase in the overall duration of reperfusion, suggests that inhibition of platelet-as well as thrombin-mediated activity effectively maximizes the thrombolytic effects of rTPA. The same statistical relation among the four groups of dogs was observed in choosing the CBF "cutoff" value as 50% of baseline (Fig 3) .
Results
Platelet Aggregation and Coagulation Studies
The results of PRP platelet aggregation in response to epinephrine plus ADP (5 and 20 ,mol/L, respectively) are 20 ,imol/L. The increase in aPTT caused by recombinant hirudin was prompt in dogs receiving full recombinant hirudin doses and gradual, over time, in dogs receiving low doses of Integrelin plus recombinant hirudin (Table 3) .
In all groups of dogs, rTPA administration, regardless of the adjunctive therapy, caused the same degree of fibrinogen depletion (60% to 65%). Neither recombinant hirudin, Integrelin, nor the combination further decreased the plasma fibrinogen levels (data not shown).
Thrombin activity, assessed by measuring changes in plasma FPA and TAT levels, is shown in Fig 5. In dogs receiving rTPA plus saline, at the end of rTPA administration (approximately at the onset of thrombolysis), FPA values were twice baseline. In rTPA-plus-Integrelin-treated dogs, after rTPA, FPA was increased by 71+21% (P=NS versus saline). In both of these groups of dogs, FPA was still 50% greater than the baseline value at the end of adjunctive therapy, indicating persistently high thrombin activity. On the other hand, full doses of recombinant hirudin virtually blocked any increase in FPA (P<.05 versus saline at any time point). In the group of dogs receiving low doses of recombinant hirudin plus Integrelin, by the end of adjunctive therapy administration, FPA levels were similar to the baseline value and significantly lower than those in saline or Integrelin groups (P<.05). The TAT also showed a pattern consistent with that of FPA. Taken together, these data indicate that significant inhibition of thrombin activity was achieved in both groups of dogs treated with recombinant hirudin (Fig 5) .
Discussion
In the present study, we showed that inhibition of specific pathways of platelet and thrombin activity successfully improves the extent and the duration of rTPA- 12 hours, and the patency of the infarct-related artery was studied 5 days later. Although the doses of recombinant hirudin used in our experiments were 10 times lower, we clearly showed through the coagulation studies the efficacy of such doses of recombinant hirudin in blocking thrombin activation (Table 3 and Fig 5) .
The maximal degree of thrombin activity was observed, regardless of the treatment received, at the onset of reperfusion in all dogs (Fig 5) . However The results of the present study showed that the reocclusion rate was significantly decreased only in dogs /, treated with the low-dose combination of Integrelin plus recombinant hirudin (Table 1) . This observation along with the superior increase in the extent of lysis of the primary thrombus obtained in the group receiving the low-dose combination of platelet JIb/lIla receptor antagonist and direct thrombin inhibitor suggest that the interaction between platelets and thrombin plays a major role in determining the efficacy of rTPA-induced thrombolysis.
Another aspect that deserves mention is that in this study, none of the active adjunctive treatments accelerated rTPA-induced thrombolysis. On the contrary, others reported efficacy of antiplatelet agents,30 direct antithrombin agents,33 or both13 in decreasing the time to reperfusion. This disagreement in the results may relate to a substantial difference in the model and in the administration of thrombolytic therapy. In the present study, to obtain a reperfusion rate comparable to that occurring in humans undergoing thrombolysis with rTPA, we removed the external occluder before initiation of thrombolytic therapy and gave rTPA as an accelerated regimen (20 versus 90 minutes as reported in the majority of the experimental studies). Under these circumstances, both the reperfusion rate and time to restoration of CBF are markedly improved. 34 In summary, the present study shows that the combination of Integrelin plus recombinant hirudin led to sustained and stable reperfusion, indicating that concomitant inhibition of both thrombin and platelet-mediated activity ameliorates the thrombolytic effect of rTPA. Furthermore, because of the very different mechanisms of action of Integrelin and recombinant hirudin, suggesting a strong additive antithrombotic effect of these two agents, our study shows that low doses of highly selective platelet and thrombin antagonists in combination may be effectively used during thrombolytic therapy.
